| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -65,631 | -39,662 |
| Net accretion of discounts on available-for-sale securities | -2,323 | -1,765 |
| Depreciation and amortization expense | 2,240 | 1,465 |
| Accrued interest on held-to-maturity investments | 0 | 0 |
| Share-based compensation | 6,657 | 4,501 |
| Other noncash expense, net | -236 | -222 |
| Accounts receivable, net | 63 | 109 |
| Interest receivable | 305 | 286 |
| Inventory | 0 | 0 |
| Prepaid expenses and other current assets | -249 | -259 |
| Accounts payable and accrued expenses | 993 | -4,548 |
| Deferred income | -1,400 | -1,400 |
| Accrued personnel expenses | 1,233 | -441 |
| Other noncurrent liabilities | 287 | 229 |
| Net cash (used in) provided by operating activities | -57,827 | -41,535 |
| Additions to property and equipment | 7,674 | 5,682 |
| Additions to other assets | 84 | 45 |
| Purchases of held-to-maturity securities | 0 | 0 |
| Proceeds from held-to-maturity securities | 0 | 0 |
| Purchases of available-for-sale securities | 99,225 | 67,094 |
| Maturities of available-for-sale securities | 119,674 | 71,520 |
| Net cash provided by (used in) investing activities | 12,691 | -1,301 |
| Repayment of note payable | 39 | 26 |
| Proceeds from sales of common stock, pursuant to exercise of warrants, net | 0 | 0 |
| Proceeds from sales of common stock, pursuant to exercise of options | 371 | 145 |
| Proceeds from the issuance of common stock and pre-funded warrants, net | 0 | 0 |
| Proceeds from the sale of common stock pursuant to at-the-market offering, net | 9,986 | 9,986 |
| Net cash provided by financing activities | 10,318 | 10,105 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -34,818 | -32,731 |
| Cash and cash equivalents at end of period | 26,762 | - |
Perspective Therapeutics, Inc. (CATX)
Perspective Therapeutics, Inc. (CATX)